CN114705787B - 基于衍生化的干血斑中12种类固醇激素的检测方法 - Google Patents
基于衍生化的干血斑中12种类固醇激素的检测方法 Download PDFInfo
- Publication number
- CN114705787B CN114705787B CN202210469442.5A CN202210469442A CN114705787B CN 114705787 B CN114705787 B CN 114705787B CN 202210469442 A CN202210469442 A CN 202210469442A CN 114705787 B CN114705787 B CN 114705787B
- Authority
- CN
- China
- Prior art keywords
- sample
- blood
- derivatization
- standard curve
- blood spot
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 119
- 239000008280 blood Substances 0.000 title claims abstract description 119
- 238000001212 derivatisation Methods 0.000 title claims abstract description 48
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000003270 steroid hormone Substances 0.000 title claims abstract description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 44
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims abstract description 40
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 24
- 238000000605 extraction Methods 0.000 claims abstract description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 22
- 238000012360 testing method Methods 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 20
- -1 hydroxyl steroid Chemical class 0.000 claims abstract description 17
- 238000007664 blowing Methods 0.000 claims abstract description 12
- DDFHBQSCUXNBSA-UHFFFAOYSA-N 5-(5-carboxythiophen-2-yl)thiophene-2-carboxylic acid Chemical compound S1C(C(=O)O)=CC=C1C1=CC=C(C(O)=O)S1 DDFHBQSCUXNBSA-UHFFFAOYSA-N 0.000 claims abstract description 11
- 238000001035 drying Methods 0.000 claims abstract description 10
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims abstract description 9
- 238000005070 sampling Methods 0.000 claims abstract description 9
- 239000007864 aqueous solution Substances 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 31
- DBPWSSGDRRHUNT-CEGNMAFCSA-N 17α-hydroxyprogesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DBPWSSGDRRHUNT-CEGNMAFCSA-N 0.000 claims description 19
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims description 18
- 229960005471 androstenedione Drugs 0.000 claims description 18
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims description 18
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 15
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 claims description 14
- 239000012071 phase Substances 0.000 claims description 14
- 229960003473 androstanolone Drugs 0.000 claims description 13
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 13
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims description 12
- 239000007789 gas Substances 0.000 claims description 12
- 229960002847 prasterone Drugs 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 9
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 claims description 9
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 9
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 9
- 229960004544 cortisone Drugs 0.000 claims description 9
- 150000002500 ions Chemical class 0.000 claims description 9
- PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 claims description 8
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 8
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 8
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 8
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 claims description 8
- 229960002478 aldosterone Drugs 0.000 claims description 8
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 8
- 229960005309 estradiol Drugs 0.000 claims description 8
- 229930182833 estradiol Natural products 0.000 claims description 8
- PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 claims description 8
- 229960001348 estriol Drugs 0.000 claims description 8
- 239000000186 progesterone Substances 0.000 claims description 8
- 229960003387 progesterone Drugs 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 claims description 7
- QUQBHBRVKLEOEI-CLSMCGPSSA-N (1R,2S,5S,6S,14R,15S,16S)-2,8,8,10,12,12-hexadeuterio-2-(2,2-dideuterio-2-hydroxyacetyl)-18-hydroxy-14-methyl-17-oxapentacyclo[14.2.1.01,5.06,15.09,14]nonadec-9-en-11-one Chemical compound [2H]C1=C2C([2H])([2H])C[C@H]3[C@@H]4CC[C@]([2H])(C(=O)C([2H])([2H])O)[C@@]44C[C@H](OC4O)[C@@H]3[C@@]2(C)CC([2H])([2H])C1=O QUQBHBRVKLEOEI-CLSMCGPSSA-N 0.000 claims description 7
- AEMFNILZOJDQLW-QEENUVPPSA-N (8R,9S,10R,13S,14S)-10-methyl-13-(113C)methyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-3,17-dione Chemical compound [13CH3][13C@@]12[13C](=O)CC[C@H]1[C@@H]1CCC3=CC(=O)CC[C@]3(C)[C@H]1CC2 AEMFNILZOJDQLW-QEENUVPPSA-N 0.000 claims description 7
- RJKFOVLPORLFTN-TZDZRSEPSA-N (8s,9s,10s,13s,14s,17s)-17-acetyl-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=[13CH][13C](=O)[13CH2]C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-TZDZRSEPSA-N 0.000 claims description 7
- LKQDFQLSEHWIRK-UKBVDAKRSA-N 3alpha,17alpha-Dihydroxy-5beta-pregnan-20-one Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@](C(=O)C)(O)[C@@]2(C)CC1 LKQDFQLSEHWIRK-UKBVDAKRSA-N 0.000 claims description 7
- VOXZDWNPVJITMN-JJHOPHOYSA-N [C@@H]12C(C(C(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3)([2H])[2H])([2H])[2H] Chemical compound [C@@H]12C(C(C(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3)([2H])[2H])([2H])[2H] VOXZDWNPVJITMN-JJHOPHOYSA-N 0.000 claims description 7
- 229960003399 estrone Drugs 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 210000003743 erythrocyte Anatomy 0.000 claims description 6
- 239000012452 mother liquor Substances 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 claims description 5
- 239000012086 standard solution Substances 0.000 claims description 5
- OMFXVFTZEKFJBZ-VWODBOJYSA-N (8s,9s,10r,11s,13s,14s,17s)-2,2,4,6,6,17-hexadeuterio-17-(2,2-dideuterio-2-hydroxyacetyl)-11-hydroxy-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C([C@]1(C)[C@@]([2H])(C(=O)C([2H])([2H])O)CC[C@H]1[C@@H]1CC2([2H])[2H])[C@H](O)[C@@H]1[C@]1(C)C2=C([2H])C(=O)C([2H])([2H])C1 OMFXVFTZEKFJBZ-VWODBOJYSA-N 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 3
- FHDLOJQUUHKEST-UHFFFAOYSA-N azanium;methanol;fluoride Chemical compound [NH4+].[F-].OC FHDLOJQUUHKEST-UHFFFAOYSA-N 0.000 claims description 3
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000007865 diluting Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 238000004811 liquid chromatography Methods 0.000 claims description 3
- 238000001819 mass spectrum Methods 0.000 claims description 3
- 239000002504 physiological saline solution Substances 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 239000000523 sample Substances 0.000 abstract description 58
- 230000000694 effects Effects 0.000 abstract description 12
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 abstract description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract description 5
- 239000012472 biological sample Substances 0.000 abstract description 3
- 238000000752 ionisation method Methods 0.000 abstract description 3
- 239000011159 matrix material Substances 0.000 abstract description 2
- 150000003431 steroids Chemical class 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 8
- 238000000622 liquid--liquid extraction Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000000638 solvent extraction Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000016998 Conn syndrome Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- SAOKZLXYCUGLFA-UHFFFAOYSA-N bis(2-ethylhexyl) adipate Chemical compound CCCCC(CC)COC(=O)CCCCC(=O)OCC(CC)CCCC SAOKZLXYCUGLFA-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- 239000002395 mineralocorticoid Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000013433 optimization analysis Methods 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 238000006146 oximation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940037129 plain mineralocorticoids for systemic use Drugs 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000013846 primary aldosteronism Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/26—Conditioning of the fluid carrier; Flow patterns
- G01N30/28—Control of physical parameters of the fluid carrier
- G01N30/34—Control of physical parameters of the fluid carrier of fluid composition, e.g. gradient
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/60—Construction of the column
- G01N30/6052—Construction of the column body
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/62—Detectors specially adapted therefor
- G01N30/72—Mass spectrometers
- G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
- G01N30/724—Nebulising, aerosol formation or ionisation
- G01N30/7266—Nebulising, aerosol formation or ionisation by electric field, e.g. electrospray
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/86—Signal analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/045—Standards internal
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N2030/042—Standards
- G01N2030/047—Standards external
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/062—Preparation extracting sample from raw material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N30/04—Preparation or injection of sample to be analysed
- G01N30/06—Preparation
- G01N2030/067—Preparation by reaction, e.g. derivatising the sample
Landscapes
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Dispersion Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
Description
羰基类固醇 | 非衍生Q1/Q3(m/z) | ESI | DP(V) | CE(V) |
AD | 287.2/97.1 | + | 65 | 35 |
DHT | 291.2/255.2 | + | 45 | 28 |
DHEA | 271/253.3 | + | 55 | 32 |
P | 315.1/97.1 | + | 85 | 46 |
17-OHP | 331.1/97.2 | + | 62 | 37 |
B | 347.1/329.3 | + | 60 | 25 |
E | 361.1/163.2 | + | 57 | 35 |
E1 | 269/145.1 | - | -100 | -50 |
17-OHPreg | 331.1/287.2 | - | -80 | -27 |
Ald | 359.1/189 | - | -78 | -25 |
流动相A/水 | 流动相B/甲醇 | E2 | E3 |
5mM甲酸铵 | 5mM甲酸铵 | 2.86E+03 | 4.23E+03 |
5mM乙酸铵+0.1%甲酸 | 5mM乙酸铵+0.1%甲酸 | 4.09E+03 | 3.55E+03 |
0.2mM氟化铵 | 0.2mM氟化铵 | 1.31E+05 | 1.05E+05 |
类固醇 | 干血斑 | 液液萃取 |
AD | 2.67E+05 | 2.12E+05 |
DHT | 2.41E+04 | 1.85E+04 |
DHEA | 1.17E+05 | 9.29E+04 |
P | 2.50E+05 | 1.21E+05 |
17-OHP | 8.38E+04 | 5.95E+04 |
B | 9.16E+04 | 4.52E+04 |
E | 1.36E+06 | 5.32E+05 |
E1 | 6.79E+05 | 5.47E+05 |
E2 | 1.04E+05 | 9.69E+04 |
E3 | 1.33E+05 | 1.42E+05 |
17-OHPreg | 5.80E+04 | 3.47E+04 |
Ald | 3.68E+05 | 2.76E+05 |
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210469442.5A CN114705787B (zh) | 2022-04-28 | 2022-04-28 | 基于衍生化的干血斑中12种类固醇激素的检测方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210469442.5A CN114705787B (zh) | 2022-04-28 | 2022-04-28 | 基于衍生化的干血斑中12种类固醇激素的检测方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114705787A CN114705787A (zh) | 2022-07-05 |
CN114705787B true CN114705787B (zh) | 2024-08-27 |
Family
ID=82176278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210469442.5A Active CN114705787B (zh) | 2022-04-28 | 2022-04-28 | 基于衍生化的干血斑中12种类固醇激素的检测方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114705787B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115541776B (zh) * | 2022-11-03 | 2024-01-19 | 北京大学第三医院(北京大学第三临床医学院) | 利用高效液相色谱-离子淌度差分质谱检测类固醇激素的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105651924A (zh) * | 2016-03-16 | 2016-06-08 | 杭州汉库医学检验所有限公司 | 血液中激素的检测方法 |
CN111398446A (zh) * | 2020-03-12 | 2020-07-10 | 南京品生医学检验实验室有限公司 | 超高效液相色谱串联质谱技术检测血清中12种类固醇激素的方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010091264A2 (en) * | 2009-02-06 | 2010-08-12 | Perkinelmer Health Sciences, Inc. | Simultaneous detection of estrogen and non estrogen steroids |
CN104807921B (zh) * | 2015-05-21 | 2016-05-11 | 上海迪安医学检验所有限公司 | 高效液相色谱串联质谱技术检测血清中10种类固醇激素的方法 |
CN104807920B (zh) * | 2015-05-21 | 2017-03-01 | 上海迪安医学检验所有限公司 | 一种试剂盒在利用高效液相色谱串联质谱技术检测血清中10种类固醇激素中的应用 |
MX2017015229A (es) * | 2015-05-27 | 2018-02-19 | Quest Diagnostics Invest Llc | Metodos para la cuantificacion espectrometrica de masas de analitos extraidos de un dispositivo de micromuestreo. |
US20170328921A1 (en) * | 2016-05-02 | 2017-11-16 | Sanis Biomedical, LLC | Methods for detecting hormones and other analytes |
CN107462653B (zh) * | 2017-07-03 | 2020-04-14 | 广西壮族自治区妇幼保健院 | 干血斑中7种类固醇激素的液相色谱串联质谱检测方法 |
CN110187043A (zh) * | 2019-04-25 | 2019-08-30 | 中南民族大学 | 一种同时检测血清中13种甾体激素的方法 |
CN111983044B (zh) * | 2019-05-24 | 2023-04-11 | 中国科学院大连化学物理研究所 | 一种基于双衍生处理分析甾体激素的检测方法 |
CN110824091A (zh) * | 2019-12-17 | 2020-02-21 | 杭州度安医学检验实验室有限公司 | 一种类固醇激素检测方法 |
CN110927289A (zh) * | 2019-12-17 | 2020-03-27 | 杭州度安医学检验实验室有限公司 | 一种类固醇激素检测试剂盒 |
CN111175419B (zh) * | 2020-03-02 | 2021-03-26 | 山东英盛生物技术有限公司 | 一种同时检测血液样品中多种类固醇激素的方法及试剂盒 |
CN111398447B (zh) * | 2020-03-12 | 2023-05-05 | 南京品生医疗科技有限公司 | 超高效液相色谱串联质谱技术检测血清中12种类固醇激素的试剂盒 |
CN112379009A (zh) * | 2020-10-15 | 2021-02-19 | 生物岛实验室 | 生物样本中类固醇激素的检测方法及该方法所用试剂盒 |
CN112611828B (zh) * | 2020-12-29 | 2021-10-08 | 大连润生康泰医学检验实验室有限公司 | 一种血液中类固醇激素的纯化富集及其检测方法 |
CN113933412B (zh) * | 2021-09-24 | 2023-04-07 | 广州金域医学检验中心有限公司 | 一种血液中类固醇激素的检测方法 |
CN113720946A (zh) * | 2021-10-08 | 2021-11-30 | 艾可泰科生物科技(江苏)有限公司 | 检测血液中多种类固醇激素的方法及试剂盒 |
CN114088859B (zh) * | 2022-01-19 | 2022-04-08 | 北京金域医学检验实验室有限公司 | 一种分离多组同分异构体并检测29种类固醇激素的方法 |
-
2022
- 2022-04-28 CN CN202210469442.5A patent/CN114705787B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105651924A (zh) * | 2016-03-16 | 2016-06-08 | 杭州汉库医学检验所有限公司 | 血液中激素的检测方法 |
CN111398446A (zh) * | 2020-03-12 | 2020-07-10 | 南京品生医学检验实验室有限公司 | 超高效液相色谱串联质谱技术检测血清中12种类固醇激素的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN114705787A (zh) | 2022-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111366671B (zh) | 同时检测血清中18种类固醇激素的化学衍生-超高效液相色谱-串联质谱法 | |
CN104807921A (zh) | 高效液相色谱串联质谱技术检测血清中10种类固醇激素的方法 | |
CN112611828B (zh) | 一种血液中类固醇激素的纯化富集及其检测方法 | |
CN110702831B (zh) | 一种超高效液相色谱-串联质谱检测血清睾酮激素的试剂盒 | |
CN114705787B (zh) | 基于衍生化的干血斑中12种类固醇激素的检测方法 | |
JP2014507657A (ja) | サンプル中のテストステロンの存在または量を決定するための方法およびシステム | |
CN110927289A (zh) | 一种类固醇激素检测试剂盒 | |
CN112611827B (zh) | 测3种雌激素的化学衍生-超高效液相色谱-串联质谱法 | |
CN112748198A (zh) | 一种液相色谱串联质谱技术检测血清中抗真菌药物的方法装置 | |
CN114487210B (zh) | 基于磁性固相萃取的类固醇激素的液相色谱串联质谱检测方法 | |
CN114674961A (zh) | 一种非衍生化同步检测血清中17种类固醇激素的试剂盒及其应用 | |
CN113720946A (zh) | 检测血液中多种类固醇激素的方法及试剂盒 | |
CN111830153A (zh) | 一种检测血清中多粘菌素b1和多粘菌素b2浓度的方法 | |
CN110208393A (zh) | 一种检测血清中5种雄激素的方法 | |
CN112964809A (zh) | 一种检测生物体液多种类固醇激素试剂盒及其使用方法 | |
CN115876933A (zh) | 一种血清中类固醇激素的检测方法 | |
CN115637267A (zh) | 一种核酸的提取试剂及其试剂盒和提取方法 | |
CN113341027A (zh) | 高效液相色谱串联质谱检测唾液中睾酮的方法及试剂盒 | |
CN116124969B (zh) | 一种同时提取并测定血清中pcos相关十二种类固醇激素的lc-ms/ms试剂盒 | |
CN116286833A (zh) | 特异性结合脱氢表雄酮的核酸适配体、试剂盒及应用 | |
CN110749690B (zh) | 一种血浆样品中度他雄胺含量的检测方法 | |
CN114965785A (zh) | 一种液相色谱质谱法测定畜禽粪便中抗球虫药含量的方法 | |
Scheerle et al. | Enzymatic conversion continuously monitored with a robotic nanoESI-MS tool: experimental status | |
CN118256489B (zh) | 一种循环核酸的提取试剂盒及循环核酸的提取方法 | |
CN113203805B (zh) | 同时测定血液中葡萄糖、果糖和1,5-脱氧葡萄糖醇的液相色谱串联质谱方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Country or region after: China Address after: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant after: Tianjin Guoke Medical Technology Development Co.,Ltd. Address before: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant before: TIANJIN GUOKE YIGONG TECHNOLOGY DEVELOPMENT Co.,Ltd. Country or region before: China |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240329 Address after: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant after: Tianjin Guoke Medical Technology Development Co.,Ltd. Country or region after: China Applicant after: Suzhou Institute of Biomedical Engineering and Technology Chinese Academy of Sciences Address before: Building 4, No.16 Wujing Road, development zone, Dongli District, Tianjin Applicant before: Tianjin Guoke Medical Technology Development Co.,Ltd. Country or region before: China |
|
GR01 | Patent grant | ||
GR01 | Patent grant |